Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05766501 · ClinicalTrials.gov registry record · Phase 3

A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

A Phase 3 study of HIV Infection, sponsored by Merck Sharp & Dohme.

Active
Registry status
Phase 3
Development phase
641
Enrollment target
20
Study locations

NCT05766501 is a Phase 3 study of HIV Infection that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 641 participants, above the 234-participant average among 73 other HIV Infection trials with a reported enrollment target (174% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05766501, a Phase 3 study of HIV Infection, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
641 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety and tolerability of DOR/ISL in adult participants with HIV-1 who had been previously treated with DOR/ISL in earlier clinical studies. There are no formal hypotheses to be tested in this study.

Conditions Studied

HIV Infection

Interventions

  • DRUG DOR/ISL

Study Locations (20)

Florida

  • Therafirst Medical Center ( Site 3110) - Fort Lauderdale
  • Midway Immunology and Research Center ( Site 3117) - Ft. Pierce
  • AHF The Kinder Medical Group ( Site 3108) - Miami
  • Floridian Clinical Research, LLC ( Site 3133) - Miami Lakes
  • Orlando Immunology Center ( Site 3106) - Orlando
  • Bliss Healthcare Services ( Site 3115) - Orlando
  • CAN Community Health - Sarasota ( Site 3118) - Sarasota
  • Triple O Research Institute, P.A ( Site 3116) - West Palm Beach

California

  • Pacific Oaks Medical Group ( Site 3123) - Beverly Hills
  • Kaiser Permanente ( Site 3124) - Los Angeles
  • Ruane Clinical Research Group, Inc ( Site 3126) - Los Angeles
  • Mills Clinical Research ( Site 3114) - Los Angeles
  • University of California Davis Health-Internal Medicine: Infectious Diseases ( Site 3137) - Sacramento

Georgia

  • Augusta University-Infectious Diseases ( Site 3135) - Augusta
  • Infectious Disease Specialists of Atlanta ( Site 3128) - Decatur
  • Mercer university, Department of internal medicine-Clinical Research ( Site 3129) - Macon
  • Chatham County Health Department - Chatham CARE Center-Infectious Disease ( Site 3105) - Savannah

Alabama

  • University of Alabama at Birmingham-UAB 1917 Research Clinic ( Site 3104) - Birmingham

Arizona

  • Pueblo Family Physicians ( Site 3102) - Phoenix

District of Columbia

  • Georgetown University Medical Center ( Site 3130) - Washington D.C.

Trial Details

FieldValue
Enrollment Target 641 participants
Start Date 2023-03-17
Est. Completion 2028-09-06
Phase Phase 3

Sponsor

Merck Sharp & Dohme

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05766501

The ClinicalTrials.gov registry entry for NCT05766501 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 641 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 234-participant average among 73 other HIV Infection trials with a reported enrollment target (174% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 1 intervention - of which DOR/ISL is the first listed.

NCT05766501 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT05766501 about?

NCT05766501 is a clinical study titled "A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)". The purpose of this study is to evaluate the safety and tolerability of DOR/ISL in adult participants with HIV-1 who had been previously treated with DOR/ISL in earlier clinical studies. There are no formal hypotheses to be tested in this study.

What is the current status of trial NCT05766501?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 641 participants. The study started on 2023-03-17. Estimated completion is 2028-09-06.

What conditions does trial NCT05766501 study?

This clinical trial studies the following conditions: HIV Infection.

What interventions are being tested in trial NCT05766501?

The interventions under investigation include: DOR/ISL (DRUG).

Who is sponsoring clinical trial NCT05766501?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05766501 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infection

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.